Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the HGS 1006-C1056 or HGS 1006-C1057 protocol through the Week 72 or Week 48 visits, respectively.~Exclusion Criteria:~* Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1 mg/kg dose of belimumab given IV every 28 days.
- 2. (Type: EXPERIMENTAL): 10 mg/kg dose of belimumab given IV every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).